Sep 15th, 2021
Starpharma today announced that the US Patent and Trademark Office has granted a new patent in relation to DEP® cabazitaxel.Read More
Aug 26th, 2021
Starpharma today released its annual report and financial results for the year ended 30 June 2021.
Aug 23rd, 2021
Starpharma today announced publication of new data demonstrating the protective efficacy of VIRALEZE™ antiviral nasal spray against SARS-CoV-2 challenge in vivo in a humanised mouse model of coronavirus infection. The results of the study have been published in the international peer-reviewed journal, Viruses, in a special issue titled, Medical Interventions for Treatment and Prevention of SARS-CoV-2 Infections (https://www.mdpi.com/1999-4915/13/8/1656).Read More
Aug 17th, 2021
Starpharma today announced results from its VIRALEZE™ clinical safety study demonstrating the product was safe and well tolerated in accordance with the primary endpoint, and also confirming that the dendrimer antiviral in VIRALEZE™, SPL7013, was not absorbed into the bloodstream following nasal application.Read More